Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesWaverley Pharma Inc

Waverley Pharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.02 CAD 0.01 ( 100.00%)
Last update at 2026-11-02T19:14:00Z
VOLUME
6000
Market Cap
0.54M

Momentum Score

…

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.02
Low
0.02
High
52 Week Price Range
0.01
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Waverley Pharma Inc. is a pharmaceutical company listed on the TSX Venture Exchange (WAVE.V); publicly available details on its operations and pipeline are limited. Investors may view the company as providing exposure to pharmaceutical development outcomes that could support long-term growth if it secures successful clinical progress, licensing or commercialization events.
Key risks include high execution and regulatory uncertainty, a likely need for additional financing, and very low trading liquidity that can amplify share-price volatility.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
1.51M
Revenue Per Share
0.03
Gross Profit TTM
0.59M
Debt / Equity
-
ROE
-136.53%
Net Debt
2.57M
ROCE
41.02%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -0.95M -2.22M -0.66M -0.80M -0.71M
Net income -0.95M -2.22M -0.66M -0.80M -0.71M
Selling general administrative 0.65M 1.13M 1.14M 0.96M 0.84M
Gross profit 0.21M 0.08M 0.28M 0.22M 0.18M
Reconciled depreciation 0.13M 0.43M 0.21M 0.07M 0.01M
Ebit - - -0.94M -0.79M -0.71M
Ebitda - - -0.72M -0.72M -0.70M
Operating income -0.74M -1.23M -0.94M -0.79M -0.71M
Interest expense 0.16M 0.08M - 0.00M 0.00M
Interest income 0.00M 0.00M - - 0.01M
Net interest income -0.16M -0.08M -0.02M -0.00M 0.01M
Total revenue 0.48M 0.41M 1.25M 1.75M 1.38M
Total operating expenses 1.22M 1.65M 2.18M 2.54M 2.08M
Cost of revenue 0.26M 0.33M 0.96M 1.53M 1.19M
Total other income expense net -0.04M -0.91M 0.29M -0.01M -0.00M
Net income from continuing ops -0.95M -2.22M -0.66M -0.80M -0.71M
Net income applicable to common shares - - - -0.80M -0.71M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 2.05M 0.95M 2.69M 3.68M 3.49M
Intangible assets 0.40M 0.26M 1.68M 1.76M 1.81M
Total liab 4.08M 2.09M 1.60M 1.89M 1.45M
Total stockholder equity -2.03M -1.14M 1.09M 1.79M 2.04M
Common stock - - 7.00M 7.00M 7.00M
Capital stock 7.00M 7.00M 7.00M 7.00M 7.00M
Retained earnings -10.34M -9.40M -7.17M -6.51M -5.71M
Good will 0.22M - - - -
Other assets - - 0.38M 0.48M -
Cash 0.24M 0.05M 0.13M 0.16M 0.71M
Total current liabilities 3.86M 2.09M 1.60M 1.89M 1.41M
Net debt 2.57M 1.55M 0.57M 0.10M -
Short long term debt 2.81M 1.60M 0.70M 0.26M -
Other stockholder equity - - - 0.49M -0.06M
Total current assets 0.73M 0.42M 0.63M 1.45M 1.68M
Net tangible assets - - - 0.03M 0.23M
Net receivables 0.05M 0.14M 0.19M 0.70M 0.46M
Long term debt - - - - 0.04M
Inventory 0.26M 0.00M 0.06M 0.33M 0.27M
Accounts payable 1.01M 0.49M 0.74M 1.06M 0.83M
Non currrent assets other 0.43M 0.27M 0.38M 0.48M -
Non current assets total 1.32M 0.54M 2.05M 2.24M 1.81M
Capital lease obligations 0.26M - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.61M 0.00M -0.23M - -
Change to liabilities - - 0.00M 0.23M 0.26M
Net borrowings 1.20M 0.94M 0.44M 0.22M 0.04M
Total cash from financing activities 1.20M 0.94M 0.44M 0.22M -0.37M
Change to operating activities - - - -0.01M -0.20M
Net income -0.95M -2.22M -0.66M -0.80M -0.71M
Change in cash 0.18M -0.08M -0.02M -0.55M -0.77M
Begin period cash flow 0.05M 0.13M 0.16M 0.71M 1.48M
End period cash flow 0.24M 0.05M 0.13M 0.16M 0.71M
Total cash from operating activities -0.41M -1.02M -0.24M -0.80M -0.36M
Depreciation 0.13M 0.43M 0.21M 0.03M 0.01M
Change to inventory -0.03M 0.06M 0.29M -0.06M -0.18M
Change to account receivables -0.08M 0.06M 0.28M -0.25M 0.47M
Other cashflows from financing activities - - - - -0.41M
Change to netincome - - - 0.06M -0.02M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.36M -0.15M 0.51M -0.09M 0.35M
Stock based compensation - - 0.00M 0.00M -0.02M
Other non cash items 0.16M 0.05M 0.02M 0.00M -0.01M
Free cash flow -0.41M -1.02M -0.24M -0.80M -0.36M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
WAVE
Waverley Pharma Inc		 0.01
100.00%		 0.02 - - 0.36 1.91 5.07 -4.11
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.01
1.96%		 0.50 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 0.01
1.59%		 0.64 - - - 15.17 - -58.16

Profile*

Waverley Pharma Inc

Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.

4-1250 Waverley Street, Winnipeg, MB, Canada, R3T 6C6

204 928 7907

https://www.waverleypharma.com

Name Title Year Born
Mr. Larry Thiessen Pres & CEO NA
Mr. Haaris Uddin B.Com., CPA Chief Financial Officer NA
Mr. Larry Thiessen M.B.A. President, CEO & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ORE
CAD 2.77
+8.86%
APM
CAD 4.95
+8.08%
NUAG
CAD 7.37
+8.06%
BZ
CAD 4.03
+8.04%
AYA
CAD 34.85
+7.96%
HUT
CAD 73.56
-17.26%
PHX
CAD 11.13
-12.22%
IVN
CAD 7.93
-10.70%
EFN
CAD 20.09
-10.39%
OBE
CAD 13.62
-6.71%

Equity Sectors*

  • Basic Materials

    +3.73%

  • Communication Services

    +1.16%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.14%

  • Energy

    -1.87%

  • Financial Services

    +1.53%

  • Healthcare

    +1.50%

  • Industrials

    +0.03%

  • Real Estate

    +0.71%

  • Technology

    +0.40%

  • Utilities

    +0.35%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…